Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Lynn Thibodeau

Physician Assistant Fleming Island, FL Physician Assistant

NPI 1811992696 CMS profile 10529451

4689 US Highway 17 Ste 2, Fleming Island, FL 32003

Open in the dashboard

General payments

$10,172

517 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lynn Thibodeau of Fleming Island, FL is reported in the CMS Open Payments database as having received $10,172 across 517 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,719 129
2024 General $2,509 123
2023 General $1,683 84
2022 General $1,731 93
2021 General $1,530 88

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lynn Thibodeau
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Lynn Thibodeau were reported at $2,719. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Lynn Thibodeau Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,530 $132 $37–$438 $132
2022 $1,731 $155 $48–$522 $149
2023 $1,683 $167 $52–$557 $160
2024 $2,509 $178 $55–$600 $164
2025 $2,719 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Merck Sharp & Dohme Corporation $880 36 payments
  2. Novartis Pharmaceuticals Corporation $762 46 payments
  3. AstraZeneca Pharmaceuticals LP $735 38 payments
  4. Daiichi Sankyo Inc. $597 35 payments
  5. E.R. Squibb & Sons, L.L.C. $389 17 payments
  6. Janssen Biotech, Inc. $337 18 payments
  7. Gilead Sciences, Inc. $324 16 payments
  8. Bayer HealthCare Pharmaceuticals Inc. $323 18 payments
  9. GlaxoSmithKline, LLC. $311 15 payments
  10. Seattle Genetics, Inc. $305 16 payments
  11. Other $5,211 262 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $10,172 517 payments
Products named General payments · program years 2021–2025
  1. KEYTRUDA $860 35 payments
  2. ENHERTU Oncology $469 28 payments
  3. OPDIVO $389 17 payments
  4. Lenvima $304 13 payments
  5. IMFINZI $278 14 payments
  6. TUKYSA $270 14 payments
  7. Fabhalta $224 12 payments
  8. LIBTAYO $220 10 payments
  9. ENHERTU Oncology $216 9 payments
  10. Lonsurf $215 11 payments
  11. Other $9,457 483 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 18 billing codes

Paid by Medicare

$20,807

Medicare's payments for the services billed

Medicare patients

23

Average age 74

Services billed

802

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Cancer 52%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 70 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ENHERTU
  • Daiichi Sankyo Inc. $144
  • AstraZeneca Pharmaceuticals LP $107
$251 — —
KEYTRUDA
  • Merck Sharp & Dohme Corporation $200
$200 — —
OPDIVO
  • E.R. Squibb & Sons, L.L.C. $92
$92 — —
Fabhalta
  • Novartis Pharmaceuticals Corporation $73
$73 — —
IMFINZI
  • AstraZeneca Pharmaceuticals LP $73
$73 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 70 with Patron

Records

517 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record